CAY10499: An Advanced Inhibitor for Human Hormone Sensitive Lipase & Lipid Immunometabolism Research

Principle Overview: Dissecting Lipid Hydrolysis with CAY10499

Lipid metabolism has emerged as a pivotal regulator of immune cell function, metabolic disease, and cancer progression. Human hormone sensitive lipase (HSL) and monoglyceride lipase (MGL) are central enzymes in the hydrolysis of stored lipids, facilitating fatty acid mobilization for energy and signaling. CAY10499, available from APExBIO, is a small molecule inhibitor designed to target both HSL and MGL with exceptional potency and selectivity. According to CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, this reagent achieves half-maximal inhibition (IC₅₀) of recombinant human HSL at 90 nM and MGL-mediated hydrolysis of 4-nitrophenyl acetate at 0.5 μM, with negligible cross-reactivity at cannabinoid receptors. Its solubility in DMSO (≥32.4 mg/mL) and ethanol (≥8.93 mg/mL) ensures flexibility in assay design, while its crystalline stability at -20°C supports reproducibility across experimental runs.

Step-by-Step: Integrating CAY10499 into Experimental Workflows

Deploying CAY10499 as an enzyme inhibitor for fatty acid mobilization studies or lipid metabolism assay reagent requires careful attention to protocol details. The following workflow highlights best practices for integrating CAY10499 into in vitro and cell-based lipid hydrolysis assays:

Protocol Parameters

• Stock preparation: Dissolve CAY10499 at 10 mM in DMSO; vortex thoroughly and store aliquots at -20°C for up to 6 months.
• Working concentration: In cell-free enzyme assays, use 50–500 nM for HSL inhibition; for MGL, a range of 0.5–2 μM is recommended depending on substrate and enzyme source.
• Cell-based experiments: Pre-incubate target cells (e.g., monocyte-derived macrophages) with 0.5–2 μM CAY10499 in complete medium (final DMSO ≤0.1%) for 30–60 minutes at 37°C before stimulation or lipid loading.
• Assay controls: Always include vehicle (DMSO) controls and, where feasible, positive controls using established HSL or MGL inhibitors for benchmarking.
• Solubility management: Avoid water as solvent; dilute stocks directly into organic-compatible assay buffer or complete culture medium.

Key Innovation from the Reference Study

The recent reference study advances our understanding of tumor-associated macrophage (TAM) differentiation by showing that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles (EVs) packed with ATP-citrate lyase (ACLY), which are internalized by monocytes and drive their polarization toward immunosuppressive TAMs. This demonstrates how metabolic enzymes delivered via intercellular communication can rewire immune cell fate. Critically, the study establishes that targeting metabolic checkpoints (e.g., ACLY) within EV-recipient cells can restrict TAM-mediated immune evasion and enhance immunotherapy outcomes. Translating this into practical assay choices, researchers can use CAY10499 to selectively block parallel lipid hydrolysis pathways (HSL, MGL), dissecting how liberated fatty acids contribute to palmitate synthesis, S-palmitoylation of immune checkpoints, and macrophage phenotype transitions. This approach enables mechanistic partitioning of ACLY-dependent versus HSL/MGL-mediated lipid fluxes in immunometabolic models.

Comparative Advantages and Advanced Applications

CAY10499 offers several advantages over traditional lipase inhibitors:

• Precision and Selectivity: Its low-nanomolar IC₅₀ values for HSL and MGL, with minimal activity at cannabinoid receptors, enable targeted interrogation of lipid hydrolysis without off-target signaling artifacts (product information).
• Translational Relevance: By controlling the release of fatty acids from lipid stores, CAY10499 provides a mechanistic link between lipid metabolism and immune cell differentiation, as demonstrated in studies of TAM polarization and atherosclerosis modeling (Lipid Hydrolysis Control: CAY10499 in Translational Immunometabolism).
• Versatility Across Assays: CAY10499 can be deployed in cell-free kinetic assays of lipase activity, cell-based lipid mobilization studies, and functional readouts of immune cell phenotype in response to metabolic perturbation. Its compatibility with standard detection platforms (e.g., 4-nitrophenyl acetate hydrolysis, radiometric substrates) streamlines integration into established workflows.
• Complementary Mechanistic Dissection: As highlighted in CAY10499: Precision Lipase Inhibition for Lipid Immunometabolic Research, combining CAY10499 with ACLY or fatty acid amide hydrolase (FAAH) inhibitors can help map the specific contribution of each lipid-processing step to immune and metabolic outcomes.

Troubleshooting and Optimization Tips

Effective use of CAY10499 requires attention to several technical considerations:

• Compound Precipitation: Ensure complete dissolution in DMSO or ethanol before dilution. If precipitation occurs upon addition to aqueous buffer, increase organic co-solvent to ≤1% (v/v), or pre-warm solutions to 37°C.
• Batch-to-Batch Variability: Use crystalline CAY10499 from APExBIO and prepare fresh aliquots for each experimental series to ensure reproducibility.
• Enzyme Source Sensitivity: Recombinant versus native HSL/MGL can display different inhibitor sensitivities. Empirically determine the optimal concentration for each source and substrate.
• Cellular Toxicity: At concentrations above 10 μM, CAY10499 may induce off-target effects or cell stress. Perform preliminary cytotoxicity assays and titrate accordingly.
• Signal-to-Noise Optimization: To maximize assay window, incubate with CAY10499 for 30–60 minutes pre-stimulation and include parallel time-course studies to determine optimal inhibition duration.

Integrating and Contrasting Recent Literature

The practical deployment of CAY10499 is reinforced by recent articles:

• Lipid Hydrolysis Control: CAY10499 in Translational Immunometabolism complements the reference study by illustrating how CAY10499 enables precise dissection of lipid metabolism’s impact on immune modulation in the tumor microenvironment, extending the ACLY-focused paradigm to parallel lipolytic pathways.
• CAY10499: Precision Lipase Inhibition for Lipid Immunometabolic Research further contrasts CAY10499’s selectivity and practical application in advanced immunometabolic assays, highlighting differentiation between HSL/MGL and ACLY inhibition strategies.
• Both articles together position CAY10499 as a next-generation research tool for atherosclerosis and metabolic disease models, offering complementary insights to the EV-ACLY paradigm advanced in the reference study.

Future Outlook: Implications and Next Steps

With the recent demonstration that EV-mediated ACLY transfer can drive immunosuppressive TAM differentiation and modulate hepatocellular carcinoma progression, the strategic deployment of selective lipase inhibitors like CAY10499 opens new avenues for interrogating the metabolic regulation of immune cell fate. As immunometabolic research continues to uncover the interplay between lipid hydrolysis, fatty acid signaling, and immune checkpoint regulation, CAY10499 is poised to become a mainstay tool in both basic discovery and translational assay development. Ongoing studies are expected to further define how inhibition of HSL and MGL influences not only lipid availability but also broader immunological outcomes (reference study), supporting the design of more effective combinatorial therapies and metabolic interventions in cancer and metabolic disease.

For researchers seeking a robust, selective, and well-characterized inhibitor for steroidogenesis research or lipid metabolism assay reagent, CAY10499 from APExBIO provides a proven platform for advancing immunometabolic discovery in complex biological systems.